Pharmaceuticals
Forge Stronger Partnership for Advanced ADC Development! GeneQuantum Healthcare and Aimed Bio collaborate to develop five innovative ADC drugs
SUZHOU, China, July 6, 2023 /PRNewswire/ -- GeneQuantum Healthcare, a leader in the innovative bioconjugation technologies for ADC new drug development, announced the expansion of its partnership with a South Korean biotech company Aimed Bio today. This strategic collaboration aims to jointly dev...
2023-07-07 10:19
1961
Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris has Completed the Phase III bridging trial Enrollment
SHANGHAI, July 6, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the completion of patient enrollment for...
2023-07-06 18:33
2033
CARING PHARMACY CELEBRATES UNIFIED CARING MEMBERSHIP PROGRAMME WITH GEORGETOWN PHARMACY AND WELLINGS PHARMACY
KUALA LUMPUR, Malaysia, July 6, 2023 /PRNewswire/ -- CARiNG Pharmacy, Georgetown Pharmacy, and Wellings Pharmacy, all subsidiaries under CARiNG Pharmacy Group, are proud to announce their newly revamped Caring Membership Mobile App which unifies all 3 pharmacies' membership programme into one. To...
2023-07-06 18:00
3081
Registrational Pivotal Phase III Study of Olverembatinib for the First-Line Treatment of Patients with Ph+ ALL Approved by the CDE in China
SUZHOU, China and ROCKVILLE, Md., July 5, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the Center for Drug Evaluation (CDE) of the Chi...
2023-07-06 10:38
1849
MGI's DNBSEQ-T7* Receives Approval for Clinical Use in South Korea
SEOUL, South Korea, July 6, 2023 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a company committed to building core tools and technology to lead life science, announced its ultra-high-throughput genetic sequencer DNBSEQ-T7 received the medical device registration certificate from the Korea Ministry of...
2023-07-06 09:00
2874
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure
Extension of BRII-179 license from VBI Vaccines to global rights bolsters Brii Bio's position to achieve best-in-class HBV functional cure in broad patient populations Company also acquires exclusive rights to PreHevbri®, a clinically differentiated, 3-antigen prophylactic vaccine, from VBI inGr...
2023-07-06 07:25
3108
Brii Biosciences Provides Latest Clinical Development and Corporate Updates
Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsA...
2023-07-06 07:19
3120
Biosion, Inc. Appoints Furqan Ahmed, PharmD as Vice President and Head of Business Development
NEWARK, Del. and NANJING, China, July 5, 2023 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global, clinical-stage biotechnology company, today announced the appointment ofFurqan Ahmed, PharmD., as the Vice President and Head of Business Development. In this position, Furqan will be responsible fo...
2023-07-05 22:05
2112
TiumBio and Hansoh Pharma Announce Clinical Trial Approval of 'HS-10518/TU2670' from NMPA in China
- Hansoh plans to develop 'TU2670 (Hansoh's code: HS-10518)' as a best-in-class novel GnRH antagonist inChina - TiumBio will complete the last patient dosing in a Phase 2a clinical trial of TU2670 in endometriosis inEurope by the end of the year BOSTON and SEONGNAM, South Korea, July 5, 2023 /P...
2023-07-05 20:00
2300
I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC
GAITHERSBURG, Md. and SHANGHAI, July 5, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced the publication of a manuscript entitled "C...
2023-07-05 20:00
1928
Jacobio Receives CDE Approval for Glecirasib's Pancreatic Cancer Pivotal Study in China
BEIJING, SHANGHAI and BOSTON, July 4, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its novel KRAS G12C inhibitor glecirasib's pivotal study for pancreatic cancer has been approved from CDE (Center for Drug Evalu...
2023-07-04 21:16
2413
China NMPA approves RareStone's pitolisant (Wakix) for the treatment of narcolepsy
-- pitolisant is the first and only treatment drug approved in mainland China for narcolepsy. SHANGHAI, July 4, 2023 /PRNewswire/ -- RareStone Group, a rare disease-focused company aiming to establish the first rare disease ecosystem in China, announced that on June 30, the Chinese National Med...
2023-07-04 20:42
1982
AFTER FIVE YEARS OF SUCCESSFUL EXPERIENCE INTERNATIONALLY, BIOCON BIOLOGICS' HULIO® BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES
BRIDGEWATER, N.J. and BENGALURU, India, July 3, 2023 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, today announced that HULIO® (adalimumab-fkjp) injection, a biosimilar to Humira® (adalimumab), is now available to patients inthe United States after five years of experien...
2023-07-04 01:22
2424
Skyline Therapeutics Receives FDA Clearance of IND for SKG0106, a Novel Intravitreally Delivered AAV Gene Therapy Candidate for Neovascular Age-related Macular Degeneration
SHANGHAI and BOSTON, July 3, 2023 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven gene therapy company committed to developing unique and novel solutions for rare and severe diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New D...
2023-07-03 19:00
1673
Henlius Forecasts Profit in 1H 2023
Spurring a Seamless R&D, Manufacturing, and Commercialisation Positive Cycle SHANGHAI, July 3, 2023 /PRNewswire/ -- Henlius (2696.HK) released a positive profit forecast. Based on the preliminary assessment of the unaudited comprehensive management accounts for the six months endedJune 30, 2023, ...
2023-07-03 18:59
4552
Henlius Forecasts Profit in 1H 2023
Spurring a Seamless R&D, Manufacturing, and Commercialisation Positive Cycle SHANGHAI, July 3, 2023 /PRNewswire/ -- Henlius (2696.HK) released a positive profit forecast. Based on the preliminary assessment of the unaudited comprehensive management accounts for the six months endedJune 30, 2023, ...
2023-07-03 17:49
2396
SHL Medical acquires 100% of the shares in Swiss company LCA Automation
SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider. The acquisition is SHL Medical's response to the growing market demand for drug delivery solutions and will support its manufacturing operations globally, especially the upcomingSwiss man...
2023-07-03 17:00
2456
Innovent and IASO Bio Announce the NMPA Approval of FUCASO®, the First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed or Refractory Multiple Myeloma
ROCKVILLE, Md. and SUZHOU, China, July 3, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2023-07-03 08:00
4420
Zymedi announced their collaboration with the National Heart, Lung, and Blood Institute through a CTA CRADA to develop ZMA001 mAb, a potential treatment for Pulmonary Arterial Hypertension (PAH), a rare, female predominant disease
SEOUL, South Korea, July 2, 2023 /PRNewswire/ -- Today Zymedi, a Korean biotech venture-backed company, announced the signing of a clinical Cooperative Research and Development Agreement (CRADA) with the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health ...
2023-07-03 08:00
2858
Lifera and CENTOGENE, Enter Strategic Collaboration - Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing
* Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly owned by the Public Investment Fund (PIF) based inRiyadh. * JV focuses on providing state-of-the-art multiomic testing services to patients, health system...
2023-07-02 14:00
3344
Week's Top Stories
Most Reposted
ASTON MARTIN ARAMCO FORMULA ONE® TEAM ANNOUNCE PEPPERSTONE AS OFFICAL TRADING PARTNER
[Picked up by 308 media titles]
2025-01-07 09:00
RuggON Unveils VORTEX Vehicle Mount Computer with AI-Enhanced, SATCOM-Ready
[Picked up by 306 media titles]
2025-01-06 21:00
Brewing Connections and Spotlighting Café Culture: MIFB 2025 Hosts MNCC in Collaboration with MSCA
[Picked up by 305 media titles]
2025-01-06 14:00
iWOW Unveils Age-Tech Innovations at CES 2025, Expanding Portfolio of IoT Solutions for Ageing-In-Place
[Picked up by 293 media titles]
2025-01-07 21:18CELEBRATE THE LUNAR NEW YEAR 2025 AT HOIANA RESORT & GOLF, WORLD'S LEADING FULLY INTEGRATED RESORT
[Picked up by 290 media titles]
2025-01-06 19:25
Most Read
Interest-Driven Consumption Sparks ¥ 500B ACG Goods Market, MINISO Rides the Wave
2025-01-03 19:33
10644
Russell Reynolds Associates Appoints Euan Kenworthy as Singapore Country Manager
2025-01-02 08:16
8340
PieX AI: Launching the World's First Personalized, On-device AI Pendant at CES 2025
2025-01-02 21:00
6622
